Cartesian Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Cartesian Therapeutics, Inc. (RNAC) had Debt Securities, Available-for-sale, Amortized Cost of $28.18 million as of 2022-12-31, per its 10-K filed 2024-03-07.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2024-03-07
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost $28.18M.
- 2022-09-30: Debt Securities, Available-for-sale, Amortized Cost $33.63M.
- 2022-06-30: Debt Securities, Available-for-sale, Amortized Cost $4.00M.
- 2022-03-31: Debt Securities, Available-for-sale, Amortized Cost $4.00M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2022-12-31 | $28.18M 10-K · filed 2024-03-07 |
| 2022-09-30 | $33.63M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $4.00M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $4.00M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $14.00M 10-K · filed 2023-03-02 |
| 2021-09-30 | $24.02M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $24.39M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $22.41M 10-Q · filed 2021-05-13 |
| 2019-06-30 | $11.48M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $16.24M 10-Q · filed 2019-05-09 |
| 2018-06-30 | $5.99M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $24.85M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $25.96M 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |